HIV-1 resistance to dolutegravir: update and new insights

被引：0
|
作者：
Wainberg, Mark A. [1 ]
Han, Ying-Shan [1 ]
机构：
[1] McGill Univ, Jewish Gen Hosp, AIDS Ctr, Lady Davis Inst Med Res, Montreal, PQ, Canada
来源：
JOURNAL OF VIRUS ERADICATION | 2015年 / 1卷 / 01期
关键词：
drug resistance; viral fitness; R263K mutation;
D O I：
暂无
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
Integrase strand transfer inhibitors (INSTIs) are the latest class of potent anti-HIV drugs. Currently, three INSTIs have been approved by the US Food and Drug Administration: raltegravir (RAL), elvitegravir (EVG) and dolutegravir (DTG). Resistance mutations to RAL and EVG emerge rapidly, and significant cross-resistance between these compounds has been documented. In addition, limited cross-resistance has been observed among DTG, a newer INSTI, and RAL and EVG even though clinical resistance to DTG, or mutations associated with DTG resistance in treatment-naive patients, has not yet been observed. This review summarises progress in studies on understanding resistance to DTG, mechanisms of possible resistance to DTG, and reasons for the absence of DTG-associated resistance mutations when the drug has been used in first-line therapy.
引用
收藏
页码：13 / 16
页数：4
相关论文
共 50 条
  • [1] An update on HIV-1 antiretroviral resistance
    Plank, Rebeca M.
    Kuritzkes, Daniel R.
    [J]. CURRENT OPINION IN HIV AND AIDS, 2006, 1 (05) : 417 - 423
  • [2] HIV-1 Resistance to Dolutegravir Is Affected by Cellular Histone Acetyltransferase Activity
    Anstett, Kaitlin
    Brenner, Bluma
    Mesplede, Thibault
    Wainberg, Mark A.
    [J]. JOURNAL OF VIROLOGY, 2017, 91 (21)
  • [3] Integrase resistance emergence with dolutegravir/lamivudine with prior HIV-1 suppression
    Revollo, Boris
    Vinuela, Laura
    de la Mora, Lorena
    Garcia, Federico
    Noguera-Julian, Marc
    Parera, Mariona
    Paredes, Roger
    Llibre, Josep M.
    [J]. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2022, 77 (06) : 1738 - 1740
  • [4] Absence of HIV-1 Drug Resistance Mutations Supports the Use of Dolutegravir in Uganda
    Ndashimye, Emmanuel
    Avino, Mariano
    Kyeyune, Fred
    Nankya, Immaculate
    Gibson, Richard M.
    Nabulime, Eva
    Poon, Art F. Y.
    Kityo, Cissy
    Mugyenyi, Peter
    Quinones-Mateu, Miguel E.
    Arts, Eric J.
    [J]. AIDS RESEARCH AND HUMAN RETROVIRUSES, 2018, 34 (05) : 404 - 414
  • [5] Mutations in the HIV-1 3′-Polypurine Tract Can Confer Dolutegravir Resistance
    Dekker, Jose G.
    Klaver, Bep
    Berkhout, Ben
    Das, Atze T.
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2022, 66 (01)
  • [6] HIV-1 Resistance Dynamics in Patients With Virologic Failure to Dolutegravir Maintenance Monotherapy
    Wijting, Ingeborg E. A.
    Lungu, Cynthia
    Rijnders, Bart J. A.
    van der Ende, Marchina E.
    Pham, Hanh T.
    Mesplede, Thibault
    Pas, Suzan D.
    Voermans, Jolanda J. C.
    Schuurman, Rob
    van de Vijver, David A. M. C.
    Boers, Patrick H. M.
    Gruters, Rob A.
    Boucher, Charles A. B.
    van Kampen, Jeroen J. A.
    [J]. JOURNAL OF INFECTIOUS DISEASES, 2018, 218 (05): : 688 - 697
  • [7] Evaluation of dolutegravir safety for the treatment of HIV-1
    Keeshin, Susana W.
    Feinberg, Judith
    [J]. EXPERT OPINION ON DRUG SAFETY, 2015, 14 (01) : 141 - 147
  • [8] Dolutegravir/rilpivirine for the treatment of HIV-1 infection
    Dowers, Ellen
    Zamora, Francis
    Barakat, Lydia Aoun
    Ogbuagu, Onyema
    [J]. HIV AIDS-RESEARCH AND PALLIATIVE CARE, 2018, 10 : 215 - 223
  • [9] Dolutegravir/Rilpivirine: A Review in HIV-1 Infection
    Blair, Hannah A.
    [J]. DRUGS, 2018, 78 (16) : 1741 - 1750
  • [10] Dolutegravir/Rilpivirine: A Review in HIV-1 Infection
    Hannah A. Blair
    [J]. Drugs, 2018, 78 : 1741 - 1750
12345